AR079706A1 - Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso - Google Patents

Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso

Info

Publication number
AR079706A1
AR079706A1 ARP100104891A ARP100104891A AR079706A1 AR 079706 A1 AR079706 A1 AR 079706A1 AR P100104891 A ARP100104891 A AR P100104891A AR P100104891 A ARP100104891 A AR P100104891A AR 079706 A1 AR079706 A1 AR 079706A1
Authority
AR
Argentina
Prior art keywords
angiogenesis
treatment
compositions
methods
diseases related
Prior art date
Application number
ARP100104891A
Other languages
English (en)
Original Assignee
Univ Nat Cheng Kung
Univ Nat Taiwan
Twi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nat Cheng Kung, Univ Nat Taiwan, Twi Biotechnology Inc filed Critical Univ Nat Cheng Kung
Publication of AR079706A1 publication Critical patent/AR079706A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Abstract

Reivindicacion 1: Una composicion para el tratamiento y/o la prevencion de una enfermedad ocular relacionada con la angiogénesis, la cual comprende una dosis baja de una variante de rodostomina que comprende una secuencia de aminoácidos seleccionada entre la SEC ID NO: 1 y la SEC ID NO: 16, o una sal farmacéuticamente aceptable de dicha variante de rodostamina. Reivindicacion 4: La composicion de acuerdo con la reivindicacion 1, en la cual dicha variante de rodostomina está conjugada con albumina o pegilada.
ARP100104891A 2009-12-23 2010-12-22 Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso AR079706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28962409P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
AR079706A1 true AR079706A1 (es) 2012-02-15

Family

ID=44151942

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104891A AR079706A1 (es) 2009-12-23 2010-12-22 Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso

Country Status (14)

Country Link
US (1) US9044436B2 (es)
EP (1) EP2515926A4 (es)
JP (1) JP5739908B2 (es)
KR (1) KR20120130752A (es)
CN (1) CN102883738A (es)
AR (1) AR079706A1 (es)
AU (1) AU2010336475A1 (es)
BR (1) BR112012015188A8 (es)
CA (1) CA2782796A1 (es)
MX (1) MX2012007416A (es)
NZ (1) NZ600544A (es)
RU (1) RU2012131251A (es)
TW (1) TWI581801B (es)
WO (1) WO2011079175A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2396347B1 (en) 2009-02-11 2017-04-12 Albumedix A/S Albumin variants and conjugates
CA2768360A1 (en) * 2009-07-20 2011-01-27 National Cheng Kung University Polypeptides selective for .alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
AU2013234299B2 (en) 2012-03-16 2017-06-22 Albumedix Ltd. Albumin variants
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
WO2015147616A1 (ko) * 2014-03-28 2015-10-01 연세대학교 산학협력단 Rgd 모티프를 포함하는 펩타이드 또는 단백질을 포함하는 신경염증 예방, 억제 또는 치료용 조성물
TWI563001B (en) 2014-08-22 2016-12-21 Univ Nat Cheng Kung Disintegrin variants and pharmaceutical uses thereof
JP6510054B2 (ja) 2014-12-31 2019-05-08 ヒュオンス カンパニー リミテッド Ｒｇｄモチーフ含有ペプチドまたはその断片を含む、皮膚しわを改善するための組成物
BR112017027567A2 (pt) * 2015-06-28 2018-09-04 Allgenesis Biotherapeutics Inc. proteínas de fusão para inibir a angiogênese
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6710030B1 (en) 1993-10-22 2004-03-23 University Of Southern California Contortrostain (CN) and methods for its use in preventing metastasis and other conditions
US5659018A (en) * 1995-08-01 1997-08-19 Genetics Institute, Inc. Mocarhagin, a cobra venom protease, and therapeutic uses thereof
US20030228298A1 (en) * 2001-09-04 2003-12-11 Mark Nesbit Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
JP2005529166A (ja) 2002-06-07 2005-09-29 ウィスコンシン アルムニ リサーチ ファウンデーション ペプチドカップリングのための試薬の化学合成
CA2606989A1 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
CA2768360A1 (en) * 2009-07-20 2011-01-27 National Cheng Kung University Polypeptides selective for .alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof

Also Published As

Publication number Publication date
CA2782796A1 (en) 2011-06-30
JP2013515739A (ja) 2013-05-09
RU2012131251A (ru) 2014-01-27
NZ600544A (en) 2014-06-27
TWI581801B (zh) 2017-05-11
US20110152192A1 (en) 2011-06-23
WO2011079175A1 (en) 2011-06-30
JP5739908B2 (ja) 2015-06-24
CN102883738A (zh) 2013-01-16
EP2515926A1 (en) 2012-10-31
TW201138801A (en) 2011-11-16
BR112012015188A8 (pt) 2016-08-09
AU2010336475A1 (en) 2012-06-14
BR112012015188A2 (pt) 2016-04-05
MX2012007416A (es) 2012-07-23
US9044436B2 (en) 2015-06-02
KR20120130752A (ko) 2012-12-03
EP2515926A4 (en) 2013-10-09

Similar Documents

Publication Publication Date Title
AR079706A1 (es) Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso
BRPI0509863A (pt) liberação de fármaco para fundo de olho
UY32833A (es) Antagonistas dp2 y usos del mismo
AR059575A1 (es) Metodo para el tratamiento de enfermedades inflamatorias
JP2013520405A5 (es)
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
AR100945A1 (es) Proteínas de fusión mic-1 y usos de las mismas
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
CO6382125A2 (es) Inhibidores de proteína quinasa
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
CL2019003091A1 (es) Terapia de combinación.
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
HRP20170328T1 (hr) Cjepivo pcsk9
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
AR068438A1 (es) Derivado de 6-pirimidinil-pirimid-2-ona
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
AR068439A1 (es) Derivado de 6-pirimidinil-pirimid-2-ona
AR087787A1 (es) Compuesto de benzotiazolona

Legal Events

Date Code Title Description
FB Suspension of granting procedure